title: Long-term Morbidity of Testicular Cancer Treatment.
abstract: Second malignant neoplasms, cardiovascular disease, neurotoxicity and ototoxicity, pulmonary complications, hypogonadism, and nephrotoxicity are potentially life-threatening long-term complications of testicular cancer and its therapy. This article describes the pathogenesis, risks, and management of these late effects experienced by long-term testicular cancer survivors, who are defined as individuals who are disease free 5 years or more after primary treatment. Testicular cancer survivors should follow applicable national guidelines for cancer screening and management of cardiovascular disease risk factors. In addition, health care providers should capitalize on the time of cancer diagnosis as a teachable moment to introduce and promote lifestyle changes.
authors.affiliation: Division of Medical Oncology, James P. Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA. Electronic address: chunkit_fung@urmc.rochester.edu.
authors.forename: Chunkit
authors.initials: C
authors.lastname: Fung
authors.affiliation: Departments of Clinical Radiotherapy and Oncology, Norwegian Radium Hospital, Postboks 4959 Nydalen, Oslo 0424, Norway.
authors.forename: Sophie D
authors.initials: SD
authors.lastname: Fossa
authors.affiliation: Department of Public Health Sciences, University of Rochester Medical Center, University of Rochester School of Medicine and Dentistry, Saunders Clinical and Translational Research Building, 265 Crittenden Boulevard, Rochester, NY 14642, USA.
authors.forename: Annalynn
authors.initials: A
authors.lastname: Williams
authors.affiliation: Department of Radiation Oncology, Rubin Center for Cancer Survivorship, University of Rochester Medical Center, Saunders Clinical and Translational Research Building, 265 Crittenden Boulevard, CU420318, Rochester, NY 14642, USA.
authors.forename: Lois B
authors.initials: LB
authors.lastname: Travis
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016903:Drug Monitoring / Q000379:methods / Q000523:psychology; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D007006:Hypogonadism / Q000139:chemically induced; D007674:Kidney Diseases / Q000139:chemically induced; D008019:Life Style; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000523:psychology; D016609:Neoplasms, Second Primary / Q000209:etiology*; D009422:Nervous System Diseases / Q000139:chemically induced*; D011788:Quality of Life; D018570:Risk Assessment; D017741:Survivors / Q000523:psychology / Q000706:statistics & numerical data; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000523:psychology
chemical_list: D000970:Antineoplastic Agents
keywords: Cardiovascular disease; Hypogonadism; Long-term morbidity; Nephrotoxicity; Neurotoxicity; Second malignant neoplasms; Survivorship; Testicular cancer